Blood-Brain Barrier
Blood–brain barrier Protective barriers of the brain.jpg Blood and CSF brain barriers Details System Neuroimmune system Identifiers Acronym(s) BBB The blood–brain barrier (BBB) is a highly selective semipermeable membrane barrier that separates the circulating blood from the brain and extracellular fluid in the central nervous system (CNS). The blood–brain barrier is formed by brain endothelial cells and it allows the passage of water, some gases, and lipid-soluble molecules by passive diffusion, as well as the selective transport of molecules such as glucose and amino acids that are crucial to neural function. Furthermore, it prevents the entry of lipophilic potential neurotoxins by way of an active transport mechanism mediated by P-glycoprotein. Astrocytes have been claimed to be necessary to create the blood–brain barrier. A few regions in the brain, including the circumventricular organs, do not have a blood–brain barrier.
Blood-Brain Barrier Products Targets
Products for Blood-Brain Barrier - Page 2
- Cat.No. Product Name Information/Activity
-
BCC6229
LDV FITC
1207610-07-8
-
BCC6332
Leukadherin 1
Leukadherin-1 is a specific agonist of complement receptor 3 (CR3) and the leukocyte surface αMβ2 integrin CD11b/CD18.
-
BCC3943
MNS
MNS is a potent and selective inhibitor of Src and Syk tyrosine kinases.
-
BCC7458
OGT 2115
OGT 2115 is a potent, cell-permeable and orally active heparanase inhibitor with an IC50 of 0.4 μM. OGT 2115 has anti-angiogenic properties (IC50 of 1 μM). OGT 2115 also inhibits heparan sulfate degradation activity.
-
BCC6275
P11
848644-86-0
-
BCC6105
PM 102
1234564-95-4
-
BCC7694
RGDS peptide
Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function, decreases systemic inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines, iNOS and MMP-9.
-
BCC7894
RWJ 50271
RWJ 50271 is an selective inhibitor of lymphocyte function-associated antigen-1/intercellular adhesion molecule-1(LFA-1/ICAM-1) interaction with an IC50 of 5.0 μM (HL60 cells).
-
BCC6216
TC-I 15
916734-43-5
-
BCC6080
TCS 2314
TCS 2314 (compound 3) is orally active and selective very late antigen-4 (VLA-4, α4β1, CD49d/CD29) antagonist with an IC50 of 4.4 nM.


